REGENXBIO Schedules September Investor Presentations in New York

REGENXBIO Inc. executives will headline a pair of investor fireside chats in New York this September to outline progress on their gene therapy pipeline. The Rockville-based firm aims to maintain market visibility as it advances late-stage clinical programs for rare and retinal diseases throughout the coming year.

September 8, 2026, 02:19 PM Bio & News 1,583 0

REGENXBIO Schedules September Investor Presentations in New York — Photo: Bio & News

The company’s leadership team is set to present at the Baird 2026 Global Healthcare Conference on September 15, followed by a session at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. Both events begin at 8:30 a.m. ET, with live webcasts available via the firm's investor relations portal. Replays will remain accessible for 30 days post-conference.

Since its 2009 founding, the company has focused on AAV gene therapy development. Current late-stage efforts include RGX-202 for Duchenne muscular dystrophy, and the ongoing partnership with Nippon Shinyaku for RGX-121 and RGX-111. Additionally, the firm continues its collaboration with AbbVie on surabgene lomparvovec, targeting wet AMD and diabetic retinopathy.

When reusing this material a link to Money Talk is required.